The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Everolimus (E) versus axitinib (A) as second-line therapy (2L) in metastatic renal cell carcinoma (mRCC): Retrospective experience at Gustave Roussy.
 
Annalisa Guida
No Relationships to Disclose
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Sanofi
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Yohann Loriot
No Relationships to Disclose
 
Christophe Massard
No Relationships to Disclose
 
Karim Fizazi
No Relationships to Disclose
 
Bernard J. Escudier
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Novartis; Pfizer